The Landscape of Exosomes Biogenesis to Clinical Applications
DOI: https://doi.org/10.2147/ijn.s463296
IF: 7.033
2024-04-23
International Journal of Nanomedicine
Abstract:Haitham Al-Madhagi Biochemical Technology Program, Faculty of Applied Sciences, Dhamar University, Dhamar, Yemen Correspondence: Haitham Al-Madhagi, Email Exosomes are extracellular vesicles that originate from various cells and mediate intercellular communication, altering the behavior or fate of recipient cells. They carry diverse macromolecules, such as lipids, proteins, carbohydrates, and nucleic acids. Environmental stressors can change the exosomal contents of many cells, making them useful for diagnosing many chronic disorders, especially neurodegenerative, cardiovascular, cancerous, and diabetic diseases. Moreover, exosomes can be engineered as therapeutic agents to modulate disease processes. State-of-art techniques are employed to separate exosomes including ultracentrifugation, size-exclusion chromatography and immunoaffinity. However, modern technologies such as aqueous two-phase system as well as microfluidics are gaining attention in the recent years. The article highlighted the composition, biogenesis, and implications of exosomes, as well as the standard and novel methods for isolating them and applying them as biomarkers and therapeutic cargo carriers. Keywords: Exosomes, extracellular vesicles, biomarkers, therapeutic cargo carriers, separation Exosomes, also known as extracellular vesicles (EVs), were initially observed half a century ago in plasma by Dr. Wolf, who denoted them as platelet dust'. 1 Since that time, investigations have revealed the presence of vesicles in all examined biological fluids, and in vitro cultivated cell lines have demonstrated varying degrees of vesicle release. 2 Although these vesicles have undergone various nomenclatures over the years, they are now commonly referred to collectively as EVs. Three principal categories of EVs have been delineated based on their size and mechanism of release: exosomes (diameter less than 150 nm), microvesicles/shedding particles, and apoptotic bodies (both considered larger than 100 nm). The latter two types are discharged directly from the plasma membrane in viable and dying cells, respectively, and will not be further explored herein (Figure 1). This examination focuses on the smallest subset within this family—exosomes, which are vesicles released into the extracellular milieu following the fusion of late endosomes/multivesicular bodies (MVBs) with the plasma membrane. This fusion process was initially observed in rat reticulocytes in 1983 3 and subsequently in sheep reticulocytes in 1985. 4 The term exosome was coined by Rose Johnstone, a trailblazer in the field, in 1987, as she found the process reminiscent of reverse endocytosis, wherein internal vesicular contents are released as opposed to external molecules being internalized within membrane-bound structures. 5 However, comprehensive understanding of this process has largely been attained in recent years. 6 Figure 1 Comparison among exosomes, microvesicles and apoptotic bodies. 7 The Figure was partly generated using Servier Medical Art, provided by Servier, licensed under a Creative Commons Attribution 3.0. Exosomes have emerged as pivotal mediators in cellular communication, orchestrating the transfer of functional proteins, metabolites, and nucleic acids to recipient cells. 8 Their far-reaching influence spans diverse physiological processes, including immune responses, 9 tissue repair, 10 stem cell maintenance, 11 central nervous system (CNS) communication, 12 and their involvement in pathological processes such as cardiovascular diseases, 13 neurodegeneration, 14 cancer, 15 and various types of inflammations. 16 The clinical potential of exosomes is underscored by their suitability as diagnostic biomarkers and carriers of therapeutic cargo. 17 Their diminished immunogenicity, attributed to biocompatibility and a protective bi-layered lipid structure safeguarding genetic cargo from degradation, renders them appealing as therapeutic vectors. Also, their petite size (Figure 2) and membrane composition enable them to traverse major biological barriers, including the blood-brain barrier. Active research in engineered exosome production focuses on assessing various therapeutic cargoes, enhancing target selectivity, and refining manufacturing processes. 18 However, challenges persist in precisely targeting specific cell types or organs while minimizing off-target biodistribution and addressing concerns related to naturally incorporated cellular genetic impurities with potential immunogenicity. 19,20 Overcoming these challenges necessitates an improved understanding of exosome biology to advance therapeutic exosome engineering. Figure 2 The -Abstract Truncated-
pharmacology & pharmacy,nanoscience & nanotechnology